瑞莎珠单抗治疗中重度斑块状银屑病的长期安全性:17项临床试验分析
基于17项I-III期临床试验的整合数据,评估瑞莎珠单抗治疗中重度斑块状银屑病的长期安全性。短期分析纳入1306例用药患者和300例安慰剂患者,长期分析纳入3072例用药患者(暴露7927患者年)。
要点
- 瑞莎珠单抗长期治疗未增加暴露调整的不良事件率(短期318 vs 长期171事件/100患者年)。
核心结论
- 瑞莎珠单抗在短期和长期治疗中均表现出良好的安全性特征。
研究设计与样本
- 短期安全性分析整合5项II期和III期临床试验数据,纳入1306例接受瑞莎珠单抗150 mg或300 mg的患者和300例安慰剂患者。
- 长期安全性分析整合17项已完成和正在进行的I-III期临床试验数据,纳入3072例接受瑞莎珠单抗治疗的患者,总暴露7927患者年。
主要发现
- 暴露调整的不良事件率未随长期治疗增加(短期318 vs 长期171事件/100患者年)。
临床怎么用
- 长期使用瑞莎珠单抗治疗中重度斑块状银屑病的安全性数据支持其临床应用,未观察到随治疗时间延长而增加的安全信号。
局限性
- 研究纳入和排除标准存在差异,且有三项研究纳入患者数≤50例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Risankizumab has demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis in randomized clinical trials. OBJECTIVES: To evaluate safety data from risankizumab psoriasis phase I-III clinical trials. METHODS: Short-term safety (through week 16) was analysed using integrated data from five phase II and III clinical trials. Long-term safety was evaluated using integrated data from 17 phase I-III completed and ongoing trials. RESULTS: Short-term safety analyses included 1306 patients receiving risankizumab 150 mg and 300 patients receiving placebo [402·2 and 92·0 patient-years (PY) of exposure, respectively]. Long-term analyses included 3072 risankizumab-treated patients (exposure: 7927 PY). The median (excluding four outliers) treatment duration was 2·9 years (range 2 days to 5·9 years). Exposure-adjusted adverse event rates did not increase with long-term treatment (318 vs. 171 events per 100 PY for short- and long-term analyses). With long-term risankizumab treatment, rates of serious adverse events were 7·8 per 100 PY, serious infections 1·2 per 100 PY, nonmelanoma skin cancer (NMSC) 0·7 per 100 PY, malignant tumours excluding NMSC 0·5 per 100 PY, and adjudicated major adverse cardiovascular events 0·3 per 100 PY, with no important identified risks. Limitations include that the study inclusion and exclusion criteria varied and that three studies enrolled ≤ 50 patients. CONCLUSIONS: Risankizumab demonstrated a favourable safety profile over short- and long-term treatment in patients with moderate-to-severe psoriasis.
引用
- Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2021. PMID: 34652810. doi:10.1111/bjd.20818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。